Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 26,661 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hyperparathyroidism, Primary, Hypercalcemia
Interventions: Cinacalcet, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Lake Forest, California • Lancaster, California • Los Gatos, California + 19 more

Conditions: Influenza, Human
Interventions: AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device; Biological · Device
Lead sponsor: PharmaJet, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Fort Collins, Colorado • Loveland, Colorado

Conditions: Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions: Lisinopril, Atenolol; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Spontaneous Urticaria
Interventions: EVO756, Placebo control; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Mobile, Alabama • Fremont, California + 38 more

Conditions: Friedreich Ataxia
Interventions: Vatiquinone, Placebo; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 7 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Los Angeles, California • Gainesville, Florida • Tampa, Florida + 2 more

Conditions: Clostridium Difficile Colitis
Interventions: FMT, placebo; Biological
Lead sponsor: MemorialCare Health System; Other
Eligibility: 1 Year to 21 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Trauma Injury, Airway Control
Interventions: Supraglottic airway device, Standard airway management; Device · Other
Lead sponsor: Jason Sperry; Other
Eligibility: 15 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Atlanta, Georgia • Chicago, Illinois • Louisville, Kentucky + 6 more

Conditions: Autism Spectrum Disorder
Interventions: cognitive behavioral therapy, Usual community care; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 7 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PTSD
Interventions: Exposure Therapy, Interpersonal Psychotherapy; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 54 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 72
States / cities: Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more

Conditions: NASH With Fibrosis, MASH With Fibrosis
Interventions: Efruxifermin, Placebo; Drug
Lead sponsor: Akero Therapeutics, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 198
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more

Conditions: Pain (Visceral, Somatic, or Neuropathic)
Interventions: Experimental NSS, Sham NSS; Device
Lead sponsor: Defense and Veterans Center for Integrative Pain Management; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson's Disease, Movement Disorder Syndrome
Interventions: Istradefylline (KW-6002); Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Parkinson Disease
Interventions: Pramipexole, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 31 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 39
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more

Conditions: Severe Acute Alcoholic Hepatitis
Interventions: ELAD, Standard of Care treatment; Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo, fostamatinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 57
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo, Victoza; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: California City, California

Conditions: Long COVID, Long COVID-19, Post Acute COVID-19 Syndrome, Post Acute Sequelae of COVID-19
Interventions: Larazotide Acetate, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 7 Years to 50 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Venous Ulcers
Interventions: Hyalomatrix extra-cellular matrix, Mepilex wound dressing; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 21 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Gout, Hyperuricemia
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more

Conditions: Breast Cancer
Interventions: Project SOAR Awakenings arm, Project SOAR comparison group; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes Mellitus
Interventions: LGD-6972, Placebo (Captisol®); Drug
Lead sponsor: Ligand Pharmaceuticals; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions: Antibiotic Prophylaxis; Drug
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Asthma
Interventions: Qvar, Flovent Diskus; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Search by objective public record fields.

Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

Jet Injection for Influenza

Hypertension in Hemodialysis Patients (Aim 3)

Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)

A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia

Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection

LITES Task Order 0005 Prehospital Airway Control Trial (PACT)

Cognitive Behavioral Therapy for Core Autism Symptoms in School-Aged Children: A Randomized, Controlled Trial

A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use

A Study of Istradefylline (KW-6002) as Monotherapy in Parkinson's Disease (PD) Patients

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

AT1001 for the Treatment of Long COVID

Effect of Hyaluronic Acid ECM on Venous Ulcers

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients